Contact
Please use this form to send email to PR contact of this press release:
Volasertib, a potential new treatment for Rhabdomyosarcoma, receives Orphan Drug Designation from the U.S. FDA
TO:
Berta Marti Fuster
Oncoheroes Biosciences Inc
+1 857-999-1378